• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Algeria Pharmaceuticals and Healthcare Report Q4 2008 - Product Image

Algeria Pharmaceuticals and Healthcare Report Q4 2008

  • ID: 666452
  • November 2008
  • Region: Algeria
  • 52 Pages
  • Business Monitor International


  • GlaxoSmithKline (GSK)
  • Groupe Saidal
  • Merck & Co
  • Novartis
  • Pfizer
  • Sanofi-Aventis
  • MORE

Algeria Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Algeria's pharmaceuticals and healthcare industry.

Algeria remains a key market in Africa, despite dropping to equal 12th place with Nigeria. It is the second-largest African country by territory, and is modernising its healthcare system through oil and gas revenues, which have risen considerably in recent years. Despite this increase in revenues the standard of healthcare provision across the country is uneven.

The main attractions of the Algerian market are it’s relatively large and young population (Algeria’s population is in excess of 34mn), its high dependence on imported medicines and steady forecast growth are key attractions.

BMI forecasts that the value of the Algerian market will be US$5.39bn. Generics will continue to represent the bulk of consumption in terms of volumes. This is especially likely since the Ministry of Health and Population has implemented measures that mean that as a condition of receiving an import licence, medicine importers must pledge that 45% of their imports will be generics. However, with aims for World Trade READ MORE >


  • GlaxoSmithKline (GSK)
  • Groupe Saidal
  • Merck & Co
  • Novartis
  • Pfizer
  • Sanofi-Aventis
  • MORE

Executive Summary
Algeria Pharmaceuticals And Healthcare Industry SWOT
Pharmaceutical Business Environment Ratings
Table: Middle East And North Africa Pharmaceutical Business Environment Ratings
Limits Of Potential Returns
Risks To Realisation Of Returns
Algeria – Market Summary
Regulatory Regime
Trade Agreements
Intellectual Property Environment
Intellectual Property Shortcomings
Pricing And Reimbursement Environment
Industry Trends And Developments
Table Algeria – Top 10 Causes Of Death For All Ages
Healthcare Sector
Domestic Pharmaceutical Sector
Pharmaceutical Retail
Foreign Pharmaceutical Sector
Biotechnology And Research
Medical Devices
Industry Forecast Scenario
Overall Market Forecast
Table: Algeria’s Drug Expenditure And Prescription Market Indicators, 2006-2012 (DZDmn unless otherwise stated)
Key Growth Factors – Industry
Table: Algeria’s Health Expenditure, 2003-2012 (US$mn unless otherwise stated)
Key Growth Factors – Macroeconomic
It’s Oil Or Nothing
Enjoying The Gold Rush
Steady Public Sector
Risks To Outlook
Table: Algeria – Economic Activity
Patented Drug Market Forecast
Table: Algeria’s Patented Drug Market, 2003-2012
Generics Market Forecasts
Table: Algeria’s Generics Market Indicators, 2003-2012
OTC Market Forecast
Table: Algeria’s OTC Market Indicators, 2003-2012 (DZDmn unless otherwise stated)
Export And Import Forecasts
Table: Algeria’s Pharmaceutical Trade Indicators, 2003-2012 (US$mn)
Other Healthcare Data Forecasts
Table: Algeria – Other Healthcare Data And Forecasts, 2003-2012
Key Risks To Forecast Scenario
Competitive Landscape
Table Leading Pharmaceutical Companies in Algeria
Company Profiles
Leading Multinationals
GlaxoSmithKline (GSK)
Merck & Co
Leading Indigenous Manufacturer
Groupe Saidal
Forecast Modelling
How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Table: Weighting Of Components

GlaxoSmithKline (GSK)
Merck & Co
Groupe Saidal

Note: Product cover images may vary from those shown


Our Clients

Our clients' logos